Protagonist Therapeutics, Inc. (PTGX)
145.86
-2.94
(-1.98%)
USD |
NASDAQ |
Sep 04, 16:00
145.86
0.00 (0.00%)
After-Hours: 17:43
Protagonist Therapeutics Cash from Investing (Quarterly) : -2.43M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.43M |
| March 31, 2026 | 90.89M |
| December 31, 2025 | 48.82M |
| September 30, 2025 | -58.56M |
| June 30, 2025 | 54.81M |
| March 31, 2025 | -94.40M |
| December 31, 2024 | -8.725M |
| September 30, 2024 | -208.71M |
| June 30, 2024 | -88.12M |
| March 31, 2024 | 6.071M |
| December 31, 2023 | -61.29M |
| September 30, 2023 | -13.56M |
| June 30, 2023 | 25.76M |
| March 31, 2023 | 9.826M |
| December 31, 2022 | 3.935M |
| September 30, 2022 | 57.28M |
| June 30, 2022 | 34.73M |
| March 31, 2022 | -4.476M |
| December 31, 2021 | 27.87M |
| September 30, 2021 | -44.71M |
| June 30, 2021 | 7.773M |
| March 31, 2021 | -6.793M |
| December 31, 2020 | -74.40M |
| Date | Value |
|---|---|
| September 30, 2020 | -54.12M |
| June 30, 2020 | -5.171M |
| March 31, 2020 | 42.73M |
| December 31, 2019 | -12.55M |
| September 30, 2019 | -32.04M |
| June 30, 2019 | -13.22M |
| March 31, 2019 | 4.108M |
| December 31, 2018 | 4.549M |
| September 30, 2018 | 9.917M |
| June 30, 2018 | 9.591M |
| March 31, 2018 | -21.84M |
| December 31, 2017 | 4.752M |
| September 30, 2017 | -0.772M |
| June 30, 2017 | 13.09M |
| March 31, 2017 | -1.25M |
| December 31, 2016 | -64.32M |
| September 30, 2016 | 3.884M |
| June 30, 2016 | -6.034M |
| March 31, 2016 | 7.147M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | -0.005M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie, Inc. | -1.197B |
| Gilead Sciences, Inc. | -10.35B |
| Johnson & Johnson | -1.11B |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| BioMarin Pharmaceutical, Inc. | -5.102B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 219.05M |
| Cash from Financing (Quarterly) | 9.743M |
| Free Cash Flow | 130.58M |
| Free Cash Flow Per Share (Quarterly) | 3.083 |
| Free Cash Flow to Equity (Quarterly) | 219.44M |
| Free Cash Flow to Firm (Quarterly) | 218.88M |
| Free Cash Flow Yield | 1.33% |